endophenazine A: a phenazine antibiotic from the arthropod; structure in first source
ID Source | ID |
---|---|
PubMed CID | 10039975 |
CHEMBL ID | 2071428 |
SCHEMBL ID | 14652344 |
MeSH ID | M0443709 |
Synonym |
---|
9-(3-methylbut-2-enyl)phenazine-1-carboxylic acid |
bdbm50390008 |
CHEMBL2071428 , |
endophenazine a |
1-phenazinecarboxylic acid, 9-(3-methyl-2-butenyl)- |
86125-71-5 |
SCHEMBL14652344 |
DTXSID20434646 |
9-(3-methylbut-2-en-1-yl)phenazine-1-carboxylic acid |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Acetylcholinesterase | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0000 | 0.9332 | 10.0000 | AID676724 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
amyloid-beta binding | Acetylcholinesterase | Homo sapiens (human) |
acetylcholinesterase activity | Acetylcholinesterase | Homo sapiens (human) |
cholinesterase activity | Acetylcholinesterase | Homo sapiens (human) |
protein binding | Acetylcholinesterase | Homo sapiens (human) |
collagen binding | Acetylcholinesterase | Homo sapiens (human) |
hydrolase activity | Acetylcholinesterase | Homo sapiens (human) |
serine hydrolase activity | Acetylcholinesterase | Homo sapiens (human) |
acetylcholine binding | Acetylcholinesterase | Homo sapiens (human) |
protein homodimerization activity | Acetylcholinesterase | Homo sapiens (human) |
laminin binding | Acetylcholinesterase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
extracellular region | Acetylcholinesterase | Homo sapiens (human) |
basement membrane | Acetylcholinesterase | Homo sapiens (human) |
extracellular space | Acetylcholinesterase | Homo sapiens (human) |
nucleus | Acetylcholinesterase | Homo sapiens (human) |
Golgi apparatus | Acetylcholinesterase | Homo sapiens (human) |
plasma membrane | Acetylcholinesterase | Homo sapiens (human) |
cell surface | Acetylcholinesterase | Homo sapiens (human) |
membrane | Acetylcholinesterase | Homo sapiens (human) |
neuromuscular junction | Acetylcholinesterase | Homo sapiens (human) |
synaptic cleft | Acetylcholinesterase | Homo sapiens (human) |
synapse | Acetylcholinesterase | Homo sapiens (human) |
perinuclear region of cytoplasm | Acetylcholinesterase | Homo sapiens (human) |
side of membrane | Acetylcholinesterase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID676725 | Antimicrobial activity against Bacillus subtilis DSM 347 incubated for 5 hrs by resazurin dye based assay | 2012 | Journal of natural products, Jul-27, Volume: 75, Issue:7 | Geranylphenazinediol, an acetylcholinesterase inhibitor produced by a Streptomyces species. |
AID676726 | Toxicity against human KIF5 cells incubated for 24 hrs by CellTiter Blue cell viability assay | 2012 | Journal of natural products, Jul-27, Volume: 75, Issue:7 | Geranylphenazinediol, an acetylcholinesterase inhibitor produced by a Streptomyces species. |
AID676724 | Inhibition of human AChE pre-incubated for 10 mins before acetylthiocholine iodide substrate addition | 2012 | Journal of natural products, Jul-27, Volume: 75, Issue:7 | Geranylphenazinediol, an acetylcholinesterase inhibitor produced by a Streptomyces species. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (80.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |